301 filings
Page 2 of 16
8-K
xvsfiw
8 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:00pm
8-K
603mxg6 kn
20 Nov 23
Regulation FD Disclosure
3:45pm
8-K
1kicm8uj5k0kchr1
2 Nov 23
Oragenics Issues Update to Shareholders
7:00am
8-K
p1waehff
5 Oct 23
Departure of Directors or Certain Officers
5:29pm
8-K
qb4bh vkqpwysv
5 Oct 23
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
6:30am
8-K
le08y2ebyu7800ttrt
29 Sep 23
Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets
4:00pm
8-K
jcgne0phlz23xoc
15 Sep 23
Termination of a Material Definitive Agreement
4:00pm
8-K
evyprwbi2 1xcw8p5f
18 Aug 23
Changes in Registrant's Certifying Accountant
4:15pm
8-K
yr1bkyz7
10 Aug 23
Departure of Directors or Certain Officers
4:30pm
8-K
be50u5ug
7 Aug 23
Oragenics, Inc. Announces Private Placement
8:09am
8-K
e8w9m86bfvgd1am7i50a
5 Jun 23
Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM
4:30pm
8-K
qfiha3yulr3dglvw
10 Apr 23
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
4:44pm
8-K
avfbj
3 Apr 23
Regulation FD Disclosure
8:30am
8-K
rv3ijy4fk28 wrivhmrz
14 Mar 23
Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE
8:57am
8-K
ddfi c8ggj143ml7jg
8 Mar 23
Oragenics Appoints Janet Huffman as Chief Financial Officer
9:22am
8-K
g6v4 hpr7
1 Mar 23
Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate
8:35am
8-K
n9221m
24 Feb 23
Entry into a Material Definitive Agreement
4:22pm
8-K
0x7sxf xy4u18
3 Feb 23
Other Events
8:47am
8-K
nbd44i6islcped5udlr
23 Jan 23
Material Modifications to Rights of Security Holders
4:05pm
8-K
s8em6ll3
23 Dec 22
Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split
4:19pm